IMMUNITYBIO, INC. Increase (Decrease) in Inventories
IMMUNITYBIO, INC. (IBRX) reported Increase (Decrease) in Inventories of $3.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-04
- IMMUNITYBIO, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was -$1.01M.
- IMMUNITYBIO, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $4.99M, a 2798.26% increase year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $7.89M, a 25.02% increase year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $63.00K, a 57.14% decline year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in inventories for fiscal 2025 was $6.33M, a 23.54% decline from fiscal 2024.
- IMMUNITYBIO, INC. increase (decrease) in inventories for fiscal 2024 was $8.27M.
- IMMUNITYBIO, INC. increase (decrease) in inventories for fiscal 2023 was $0.00.
- IMMUNITYBIO, INC. increase (decrease) in inventories for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.97M 10-Q · filed 2026-08-04 | $11.87M derived: sum of 3 quarters · filed 2026-08-04 | $11.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $4.99M 10-Q · filed 2026-05-07 | $12.88M derived: sum of 2 quarters · filed 2026-05-07 | $12.94M derived: sum of 3 quarters · filed 2026-05-07 | $11.14M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $7.96M derived: sum of 2 quarters · filed 2026-02-23 | $6.15M derived: sum of 3 quarters · filed 2026-08-04 | $6.33M 10-K · filed 2026-02-23 |
| 2025-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.74M derived: sum of 2 quarters · filed 2026-08-04 | -$1.57M 10-Q · filed 2025-11-05 | $4.75M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$1.63M 10-Q · filed 2026-08-04 | $4.68M derived: sum of 3 quarters · filed 2026-08-04 | $4.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $172.00K 10-Q · filed 2026-05-07 | $6.49M derived: sum of 2 quarters · filed 2026-05-07 | $6.63M derived: sum of 3 quarters · filed 2026-05-07 | $8.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $6.46M derived: sum of 2 quarters · filed 2026-02-23 | $8.27M derived: sum of 3 quarters · filed 2026-02-23 | $8.27M 10-K · filed 2026-02-23 |
| 2024-09-30 | $147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.96M derived: sum of 2 quarters · filed 2025-11-05 | $1.96M 10-Q · filed 2025-11-05 | $1.96M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.81M 10-Q · filed 2025-08-05 | $1.81M derived: sum of 3 quarters · filed 2026-02-23 | $1.81M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |